Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis.

Kemps PG, Zondag TC, Steenwijk EC, Andriessen Q, Borst J, Vloemans S, Roelen DL, Voortman LM, Verdijk RM, van Noesel CJM, Cleven AHG, Hawkins C, Lang V, de Ru AH, Janssen GMC, Haasnoot GW, Franken KLMC, van Eijk R, Solleveld-Westerink N, van Wezel T, Egeler RM, Beishuizen A, van Laar JAM, Abla O, van den Bos C, van Veelen PA, van Halteren AGS.

Front Immunol. 2020 Jan 10;10:3045. doi: 10.3389/fimmu.2019.03045. eCollection 2019.

2.

Molecular findings in maxillofacial bone tumours and its diagnostic value.

Cleven AHG, Schreuder WH, Groen E, Kroon HM, Baumhoer D.

Virchows Arch. 2020 Jan;476(1):159-174. doi: 10.1007/s00428-019-02726-2. Epub 2019 Dec 14. Review.

3.

Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.

Lam SW, Cleven AHG, Kroon HM, Briaire-de Bruijn IH, Szuhai K, Bovée JVMG.

Virchows Arch. 2019 Nov 25. doi: 10.1007/s00428-019-02684-9. [Epub ahead of print]

PMID:
31768625
4.

Corresponding anaplastic lymphoma kinase-tropomyosin 3 (ALK-TPM3) fusion in a patient with a primary cutaneous anaplastic large-cell lymphoma and a Spitz nevus.

Melchers RC, Willemze R, van Doorn R, Jansen PM, Cleven AHG, Solleveld N, Vermeer MH, Quint KD.

JAAD Case Rep. 2019 Oct 24;5(11):970-972. doi: 10.1016/j.jdcr.2019.09.021. eCollection 2019 Nov. No abstract available.

5.

A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.

Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, Salas S, Bonhomme B, Gomez-Brouchet A, Laurent C, Le Guellec S, Audard V, Giraud A, Ramos-Oliver I, Cleton-Jansen AM, Savci-Heijink DC, Kroon HM, Baud J, Pissaloux D, Pierron G, Sherwood A, Coindre JM, Bovée JVMG, Larousserie F, Tirode F.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0323-8. [Epub ahead of print]

PMID:
31383960
6.

High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.

Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F, Janssen L, van der Schaaf A, Jansen E, Groenen PJTA, Eijkelenboom A, Stevens W, Hess CJ, van Krieken JH, Vermaat JSP, Cleven AHG, de Groen RAL, Neviani V, de Jong D, van Deventer S, Scheijen B, van Spriel AB.

Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31.

7.

Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.

Lam SW, van Langevelde K, Suurmeijer AJH, Cleven AHG, Bovée JVMG.

Histopathology. 2019 Dec;75(6):843-852. doi: 10.1111/his.13952. Epub 2019 Sep 13.

8.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.

9.

Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study.

Bosma SE, Cleven AHG, Dijkstra PDS.

Clin Orthop Relat Res. 2019 Jul;477(7):1548-1559. doi: 10.1097/CORR.0000000000000766.

PMID:
31107331
10.

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.

Luk SJ, van der Steen DM, Hagedoorn RS, Jordanova ES, Schilham MW, Bovée JV, Cleven AH, Falkenburg JF, Szuhai K, Heemskerk MH.

Oncoimmunology. 2018 Sep 11;7(12):e1507600. doi: 10.1080/2162402X.2018.1507600. eCollection 2018.

11.

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing.

Lam SW, Cleton-Jansen AM, Cleven AHG, Ruano D, van Wezel T, Szuhai K, Bovée JVMG.

J Mol Diagn. 2018 Sep;20(5):653-663. doi: 10.1016/j.jmoldx.2018.05.007. Epub 2018 Aug 20.

12.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

13.

High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP.

Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. No abstract available.

PMID:
29514783
14.

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, Van Beelen E, van Boven H, Haas RL, Italiano A, Cleton-Jansen AM, Bovée JVMG.

Oncoimmunology. 2017 Oct 26;7(2):e1386828. doi: 10.1080/2162402X.2017.1386828. eCollection 2018.

15.

Special variant of histiocytosis.

Quint KD, Cleven AH, Vermeer MH.

BMJ Case Rep. 2017 Oct 25;2017. pii: bcr-2017-221538. doi: 10.1136/bcr-2017-221538.

16.

Hematopoietic Tumors Primarily Presenting in Bone.

Cleven AHG, Hogendoorn PCW.

Surg Pathol Clin. 2017 Sep;10(3):675-691. doi: 10.1016/j.path.2017.04.011. Epub 2017 Jun 27. Review.

PMID:
28797508
17.

Current Pathologic Scoring Systems for Metal-on-metal THA Revisions are not Reproducible.

Smeekes C, Cleven AHG, van der Wal BCH, Dubois SV, Rouse RW, Ongkiehong BF, Wolterbeek R, Nelissen RGHH.

Clin Orthop Relat Res. 2017 Dec;475(12):3005-3011. doi: 10.1007/s11999-017-5432-4. Epub 2017 Jul 7.

18.

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.

Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JVMG.

Clin Sarcoma Res. 2017 May 4;7:8. doi: 10.1186/s13569-017-0074-6. eCollection 2017.

19.

Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.

Lou S, Balluff B, Cleven AHG, Bovée JVMG, McDonnell LA.

J Am Soc Mass Spectrom. 2017 Feb;28(2):376-383. doi: 10.1007/s13361-016-1544-4. Epub 2016 Nov 21.

20.

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.

Sundara YT, Kostine M, Cleven AH, Bovée JV, Schilham MW, Cleton-Jansen AM.

Cancer Immunol Immunother. 2017 Jan;66(1):119-128. doi: 10.1007/s00262-016-1925-3. Epub 2016 Nov 16.

21.

High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.

Lou S, Cleven AH, Balluff B, de Graaff M, Kostine M, Briaire-de Bruijn I, McDonnell LA, Bovée JV.

Clin Sarcoma Res. 2016 Oct 1;6:17. eCollection 2016.

22.

An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging.

Lou S, Balluff B, Cleven AHG, Bovée JVMG, McDonnell LA.

Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):957-966. doi: 10.1016/j.bbapap.2016.09.020. Epub 2016 Oct 8.

PMID:
27725306
23.

Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma.

Slot-Steenks MM, Hamdy NA, van de Sande MA, Vriens D, Cleven AH, Appelman-Dijkstra NM.

Endocrine. 2016 Dec;54(3):642-647. doi: 10.1007/s12020-016-1092-5. Epub 2016 Oct 5.

24.

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV.

Mod Pathol. 2016 Sep;29(9):1113. doi: 10.1038/modpathol.2016.103. No abstract available.

25.

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.

26.

Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.

Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovée JV.

Mod Pathol. 2016 Sep;29(9):1028-37. doi: 10.1038/modpathol.2016.108. Epub 2016 Jun 17.

27.

ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias.

Koning MT, Kiełbasa SM, Boersma V, Buermans HPJ, van der Zeeuw SAJ, van Bergen CAM, Cleven AHG, Kluin PM, Griffioen M, Navarrete MA, Veelken H.

Br J Haematol. 2017 Sep;178(6):983-986. doi: 10.1111/bjh.14180. Epub 2016 Jun 15. No abstract available.

PMID:
27301611
28.

High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging.

Lou S, Balluff B, de Graaff MA, Cleven AH, Briaire-de Bruijn I, Bovée JV, McDonnell LA.

Proteomics. 2016 Jun;16(11-12):1802-13. doi: 10.1002/pmic.201500514.

PMID:
27174013
29.

Targeting survivin as a potential new treatment for chondrosarcoma of bone.

de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV.

Oncogenesis. 2016 May 9;5:e222. doi: 10.1038/oncsis.2016.33.

30.

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV.

Mod Pathol. 2016 Jun;29(6):582-90. doi: 10.1038/modpathol.2016.45. Epub 2016 Mar 18. Erratum in: Mod Pathol. 2016 Sep;29(9):1113.

31.

Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.

Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV.

Am J Surg Pathol. 2015 Nov;39(11):1576-83. doi: 10.1097/PAS.0000000000000512.

PMID:
26457357
32.

DOG1 expression in giant-cell-containing bone tumours.

Cleven AH, Briaire-de Bruijn I, Szuhai K, Bovée JV.

Histopathology. 2016 May;68(6):942-5. doi: 10.1111/his.12873. Epub 2015 Dec 21. No abstract available.

PMID:
26402312
33.

Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.

Cleven AH, Zwartkruis E, Hogendoorn PC, Kroon HM, Briaire-de Bruijn I, Bovée JV.

Histopathology. 2015 Oct;67(4):483-90. doi: 10.1111/his.12666. Epub 2015 Mar 23.

PMID:
25648524
34.

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.

Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RP.

Mod Pathol. 2015 Apr;28(4):552-63. doi: 10.1038/modpathol.2014.153. Epub 2014 Nov 21.

35.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

36.

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Draht MX, Smits KM, Tournier B, Jooste V, Chapusot C, Carvalho B, Cleven AH, Derks S, Wouters KA, Belt EJ, Stockmann HB, Bril H, Weijenberg MP, van den Brandt PA, de Bruïne AP, Herman JG, Meijer GA, Piard F, Melotte V, van Engeland M.

Mol Oncol. 2014 May;8(3):679-88. doi: 10.1016/j.molonc.2014.01.011. Epub 2014 Feb 2.

37.

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M.

Cancer Metastasis Rev. 2014 Mar;33(1):161-71. doi: 10.1007/s10555-013-9462-4. Review.

38.

Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance.

Dubois L, Magagnin MG, Cleven AH, Weppler SA, Grenacher B, Landuyt W, Lieuwes N, Lambin P, Gorr TA, Koritzinsky M, Wouters BG.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1219-27. doi: 10.1016/j.ijrobp.2008.12.003.

PMID:
19251093
39.

Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response.

Smits KM, Cleven AH, Weijenberg MP, Hughes LA, Herman JG, de Bruïne AP, van Engeland M.

Pharmacogenomics. 2008 Dec;9(12):1903-16. doi: 10.2217/14622416.9.12.1903. Review.

PMID:
19072647
40.

Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis.

Cleven AH, Wouters BG, Schutte B, Spiertz AJ, van Engeland M, de Bruïne AP.

Br J Cancer. 2008 Sep 2;99(5):727-33. doi: 10.1038/sj.bjc.6604547. Epub 2008 Aug 19.

41.

Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.

Cleven AH, van Engeland M, Wouters BG, de Bruïne AP.

Cell Oncol. 2007;29(3):229-40.

42.

Cardiovascular outcome stratification using the ankle-brachial pressure index.

Cleven AH, Kester AD, Hooi JD, Knottnerus JA, van den Brandt PA, Stoffers HE.

Eur J Gen Pract. 2005 Sep-Dec;11(3-4):107-12.

PMID:
16671313

Supplemental Content

Loading ...
Support Center